Kumaraguru Raja

Stock Analyst at Brookline Capital

(1.91)
# 3282
Out of 5,446 analysts
21
Total ratings
Success rate
Average return
17 Stocks
Name Action PT Current % Upside Ratings Updated
INTS Intensity Therapeuti...
Upgrades: Buy
3
n/a n/a 1 Aug 12, 2025
PALI Palisade Bio
Maintains: Buy
16 16
0.72 2122.22% 2 May 13, 2025
QNCX Quince Therapeutics
Initiates Coverage On: Buy
9
1.63 452.15% 1 Dec 18, 2024
SABS SAB Biotherapeutics
Initiates Coverage On: Buy
8
2.01 298.01% 1 Jun 7, 2024
FBRX Forte Biosciences
Initiates Coverage On: Buy
100
11.7 754.7% 2 May 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Aug 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
150
n/a n/a 2 Jul 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
15
3.33 350.45% 1 Jun 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
9
1.9 373.68% 1 Mar 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
21
3.34 528.74% 1 Jan 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
15
n/a n/a 1 Jan 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
90
33 172.73% 1 Dec 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
290 310
3.53 8681.87% 2 May 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
33600
5.41 620972.09% 1 Sep 21, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
320
0.53 60277.36% 1 Mar 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
120
n/a n/a 1 Mar 25, 2021